Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

Slager, PhD, endowed professor of lymphoma research at Mayo Clinic, discusses the use of polygenic risk scoring to assess ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

Reid Merryman, MD, discusses which patients are typically monitored for minimal residual disease and whether there are ...

ENGOT-cx11 is a randomized, double-blind, placebo-controlled trial that enrolled patients aged 18 years or older diagnosed ...

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study ...

Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective ...

Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring ...

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its ...